RECRUITING

Antibiotic Concentrations After MassivE Transfusion Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Combat and civilian trauma frequently result in open wounds that are at risk for infection. Data from the Department of Defense Trauma Registry demonstrate that 74% of combat trauma casualties have an open wound. The Committee on Tactical Combat Casualty Care, the Prolonged Field Care Working Group, and the Joint Trauma System clinical practice guidelines recommend antibiotic prophylaxis for open wounds after trauma. The civilian setting has similar risks of open wound infection after trauma. In parallel, current practice guidelines recommend the aggressive use of balanced blood products during resuscitation. It remains unclear how the replacement of blood after hemorrhage through transfusion may affect antibiotic concentrations. Data is necessary to better understand this relationship to enhance wound prophylaxis antibiotic dosing, particularly in severely wounded casualties who receive blood products during massive transfusions. It remains unclear how these resuscitation methods may alter pharmacokinetics. The investigators hypothesize that drug concentrations decrease in direct relation to the amount of blood transfused during low-volume, massive, and supermassive transfusion after trauma compared to patients who receive no blood products. The investigators seek to understand the relationship between drug concentrations and blood product administration using a non-compartmentalized model in the setting of hemorrhage. Specifically, they will (1) obtain drug concentrations at regular intervals during the first 12-18 hours after administration of antibiotics, (2) determine how much blood products and fluids are transfused during the 12 hours prior to antibiotic and 24 hours post-administration, and (3) perform data modeling to understand the relationship between blood transfusions and drug concentrations to inform data-driven dosing models. Liquid chromatography methods will be developed to measure drug concentrations. The investigators will conduct a prospective, multicenter study at two large trauma centers - Brooke Army Medical Center and the University of Colorado Hospital. They will seek to enroll any participant who is hospitalized or anticipated hospital admission for acute trauma and receives an antibiotic on the study list during their index hospitalization. They will then model the drug levels against the amount of blood and fluid infused to create an understanding of the pharmacokinetics of antibiotic wound prophylaxis.

Official Title

Antibiotic Concentrations After MassivE Transfusion (ACME) Study

Quick Facts

Study Start:2024-09-30
Study Completion:2027-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06699901

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Receives ampicillin/sulbactam, cefazolin, cefepime, ceftriaxone, clindamycin, ertapenem, levofloxacin, metronidazole or pipercillin/tazobactam at any dose
  2. * Hospitalized or anticipated hospital admission
  1. * Received the same antibiotic within the past 5 half-lives of the drug (e.g. received the same antibiotic during a recent interval)
  2. * \<18 years of age
  3. * Known pregnancy
  4. * Known Prisoner

Contacts and Locations

Study Contact

Steven G Schauer, MD
CONTACT
5172902520
steven.g.schauer.mil@army.mil
Jessica Mendez, MS
CONTACT
jessica.mendez32.ctr@health.mil

Principal Investigator

Julie A Rizzo, MD
PRINCIPAL_INVESTIGATOR
Brooke Army Medical Center

Study Locations (Sites)

University of Colorado Hospital
Aurora, Colorado, 80045
United States
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
United States

Collaborators and Investigators

Sponsor: Brooke Army Medical Center

  • Julie A Rizzo, MD, PRINCIPAL_INVESTIGATOR, Brooke Army Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-30
Study Completion Date2027-09-30

Study Record Updates

Study Start Date2024-09-30
Study Completion Date2027-09-30

Terms related to this study

Additional Relevant MeSH Terms

  • Adverse Effects in the Therapeutic Use of Other and Unspecified Agents Affecting Blood Constituents